Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones / Why Biotech Startups Are Moving to Pre-Filled Drug Trials
Transcript
- Lucas: So the ARKG genomics ETF is up nearly eighteen percent this week. That's not a fluke — there's real money rotating back into early-stage biotech. And with that, we're seeing a funding model that would have sounded reckless five years ago. Luna: What are we talking about — pre-revenue companies with no clinical data getting term sheets? Lucas: Actually more aggressive than that. Startups are now raising Series A rounds specifically to pre-fill patient cohorts for clinical trials before they've even filed an Investigational New Drug application with the FDA. Luna: Wait — so they're enrolling patients without regulatory clearance? How is that legal? Lucas: It's not a loophole, exactly. There's a regulatory pathway called 'pre ind enrollment' that the FDA allows under specific circumstances — usually for rare diseases where patient populations are tiny and you'd lose years if you waited for full approval. The startup essentially pays a contract research organization to identify, screen, and get preliminary consent from patients, but the actual dosing doesn't begin until the IND is cleared. Luna: So it's like a waiting list that costs millions of dollars to build. Lucas: Exactly. And the bet is that once you have eighty percent of your Phase 2 trial already lined up, the FDA is more likely to approve your IND because the social cost of denying it — patients who've already been told they might get the drug — becomes politically visible. Luna: That sounds like regulatory arbitrage. Has anyone actually done this? Lucas: Yes — there's a startup called Beacon Therapeutics, based in Cambridge, Massachusetts. They're working on a gene therapy for a rare form of retinitis pigmentosa. They raised a sixty-million-dollar Series A in March, led by ARCH Venture Partners, and they explicitly told investors that half the budget would go toward pre-filling a thirty-patient cohort before filing the IND. Luna: And did the FDA push back? Lucas: Not yet. The IND was filed last month, and the FDA accepted it for review. The interesting thing is that the agency's own guidance on pre ind activities is deliberately vague — it says 'certain preparatory steps may be taken' without defining what those steps are. Beacon's lawyers interpreted that as covering full patient identification and informed consent. Luna: I can see why VCs like this. It compresses the timeline from Series A to pivotal data by maybe twelve to eighteen months. Lucas: Exactly. And in rare disease, where the addressable patient population might be a few hundred people globally, the first mover who locks up those patients essentially creates a barrier to entry. Even if your drug isn't the best, if you've already enrolled the only thirty patients in North America who meet the criteria, your competitors have to run trials in Europe or Asia. Luna: That's a brutal competitive dynamic. But it also raises ethical questions — are patients giving truly informed consent when the drug hasn't even been approved for testing? Lucas: It's a real concern. The CROs involved use a two-stage consent process: first, a general consent to be contacted and share medical records; then, a full consent once the IND is approved. But critics argue that the initial contact itself creates therapeutic misconception — patients assume they'll get the drug, even though the FDA could still reject the IND. Luna: And if the FDA does reject it, the startup has spent millions building a cohort they can't use. That's a huge risk for investors. Lucas: Which is why only deep-pocketed VCs like ARCH can play this game. They're essentially writing a call option on regulatory approval. If the IND goes through, they've saved a year of enrollment time. If it doesn't, they lose the entire CRO investment — but that's priced into the expected value of the portfolio. Luna: So this is more of a strategy for top-quartile funds than for most angel syndicates. Lucas: Right. And it's not just biotech — we're seeing similar pre-commitment strategies in deep tech. Look at the headlines today: South Korean tech giants committing over five hundred and fifty billion dollars to build domestic memory chip capacity, partly to pre-empt the so-called 'RAMageddon' they're predicting. Same logic: spend big upfront to lock in supply chains before the market clears. Luna: Interesting. So the broader theme is that in capital-intensive, regulatory-gated industries, the competitive advantage is shifting from science to operational speed — how fast you can de-risk the regulatory path. Lucas: Exactly. And that's why we're seeing more founders with operational backgrounds — people who've run CROs or worked at the FDA — getting funded over pure PhDs. The science is table stakes; the regulatory strategy is the differentiator. Luna: Speaking of which — I know we're not a biotech podcast, but this kind of strategic thinking about risk applies to any founder raising a Series A right now, especially in a market where ARKK is up five percent this week but still way off its highs. Investors are looking for asymmetric bets. Lucas: Yeah, and if you're a founder listening and thinking about how to apply this to your own capital-intensive roadmap — whether it's hardware, biotech, or even regulated fintech — the lesson is: identify the biggest pre-revenue risk, and figure out how to spend money to reduce it before you ask VCs to write the big check. Luna: And if these conversations are useful for what you're building or running, we keep the show free and ad-free. A couple of dollars a month at buy me a coffee dot com slash fexingo genuinely covers hosting and research. No perks, no tiers — just keeps us going. Lucas: It does, and we're grateful. So back to Beacon — they're now awaiting the FDA's decision, expected in the next sixty days. If it's approved, we'll see a wave of copycats. If it's rejected, it might set a precedent that shuts down this strategy for years. Luna: What's the timeline for their actual Phase 2 data, assuming approval? Lucas: They've projected top-line data by the end of 2027. That's fast — typically you'd be looking at 2029 or later for a program starting from scratch. So the efficiency gain is real, if the regulatory gamble pays off. Luna: And for the rest of us watching from outside biotech — it's a reminder that the most interesting innovations in fundraising aren't about new legal structures like SAFEs or rolling funds. They're about rethinking what you can de-risk before you even raise. Lucas: Exactly. Pre-fill the cohort, pre-commit the supply chain, pre-negotiate the customer contracts — whatever the equivalent is in your industry. That's where the next generation of Series A winners are being built.